These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7590480)

  • 21. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
    Fiorica JV; Brunetto VL; Hanjani P; Lentz SS; Mannel R; Andersen W;
    Gynecol Oncol; 2004 Jan; 92(1):10-4. PubMed ID: 14751131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.
    Thigpen JT; Brady MF; Homesley HD; Malfetano J; DuBeshter B; Burger RA; Liao S
    J Clin Oncol; 2004 Oct; 22(19):3902-8. PubMed ID: 15459211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemohormone therapy of metastatic melanoma with megestrol acetate plus dacarbazine, carmustine, and cisplatin.
    Nathanson L; Meelu MA; Losada R
    Cancer; 1994 Jan; 73(1):98-102. PubMed ID: 8275444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma.
    Wood L; Palmer M; Hewitt J; Urtasun R; Bruera E; Rapp E; Thaell JF
    Br J Cancer; 1998 Feb; 77(4):627-31. PubMed ID: 9484821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic or recurrent endometrial carcinoma. Preliminary report.
    Piver MS; Lele S; Barlow JJ
    Obstet Gynecol; 1980 Sep; 56(3):370-2. PubMed ID: 7422177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.
    Vanhoefer U; Rougier P; Wilke H; Ducreux MP; Lacave AJ; Van Cutsem E; Planker M; Santos JG; Piedbois P; Paillot B; Bodenstein H; Schmoll HJ; Bleiberg H; Nordlinger B; Couvreur ML; Baron B; Wils JA
    J Clin Oncol; 2000 Jul; 18(14):2648-57. PubMed ID: 10894863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of adjuvant chemotherapy using pirarubicin, cisplatin, and etoposide (PEP) for stage IVB endometrial carcinoma: a case report.
    Umesaki N; Tanaka T; Miyama M; Ogita S
    Eur J Gynaecol Oncol; 2000; 21(3):303-4. PubMed ID: 10949401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group.
    Thigpen JT; Brady MF; Alvarez RD; Adelson MD; Homesley HD; Manetta A; Soper JT; Given FT
    J Clin Oncol; 1999 Jun; 17(6):1736-44. PubMed ID: 10561210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose megestrol acetate therapy of ovarian carcinoma: a phase II study by the Northern California Oncology Group.
    Sikic BI; Scudder SA; Ballon SC; Soriero OM; Christman JE; Suey L; Ehsan MN; Brandt AE; Evans TL
    Semin Oncol; 1986 Dec; 13(4 Suppl 4):26-32. PubMed ID: 3099393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002).
    Park JY; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Seong SJ; Kim TJ; Kim JW; Kim SM; Bae DS; Nam JH
    Eur J Cancer; 2013 Mar; 49(4):868-74. PubMed ID: 23072814
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination therapy with paclitaxel, carboplatin and megestrol acetate for the management of advanced stage or recurrent carcinoma of the endometrium: a phase II study.
    Bevis KS; Kilgore LC; Alvarez RD; Straughn JM; Leath CA
    J Reprod Med; 2014; 59(3-4):113-20. PubMed ID: 24724218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up.
    Sorbe B; Andersson H; Boman K; Rosenberg P; Kalling M
    Int J Gynecol Cancer; 2008; 18(4):803-8. PubMed ID: 17944917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intraperitoneal and systemic chemotherapy for advanced endometrial adenocarcinoma: a case report.
    Vaughn CB; Chapman JL; Herschman BR; Bonczak MJ; Treisman EJ; Groshko GA; Nirenberg PL
    Med Pediatr Oncol; 1990; 18(1):68-71. PubMed ID: 2294393
    [No Abstract]   [Full Text] [Related]  

  • 34. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The combination paclitaxel, carboplatin and megestrol acetate is effective in women with recurrent uterine papillary serous adenocarcinoma.
    Eltabbakh GH; Moody J; Garafano LL; Hammond JM
    Eur J Gynaecol Oncol; 1999; 20(1):18-9. PubMed ID: 10422674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hormonal therapy and chemotherapy of endometrial cancer].
    Krauss T; Huschmand H; Hinney B; Viereck V; Emons G
    Zentralbl Gynakol; 2002 Jan; 124(1):45-50. PubMed ID: 11873314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study.
    Nagao S; Nishio S; Michimae H; Tanabe H; Okada S; Otsuki T; Tanioka M; Fujiwara K; Suzuki M; Kigawa J
    Gynecol Oncol; 2013 Dec; 131(3):567-73. PubMed ID: 24076450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Combination with medroxyprogesterone acetate and chemotherapy making possible complete removal of uterine corpus carcinoma].
    Tajima H; Okada T; Fujimori Y; Tomioka Y; Hirano M; Yoshida T; Ikeda S; Hata T
    Gan To Kagaku Ryoho; 1989 Jul; 16(7):2461-4. PubMed ID: 2526620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of recombinant IFN-alpha2a with etoposide/cisplatin induction and interferon/megestrol acetate maintenance in extensive small cell lung cancer.
    Khuri FR; Fossella FV; Lee JS; Murphy WK; Shin DM; Markowitz AB; Glisson BS
    J Interferon Cytokine Res; 1998 Apr; 18(4):241-5. PubMed ID: 9568726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What is the clinical value of adding tamoxifen to progestins in the treatment [correction for treament] of advanced or recurrent endometrial cancer?
    Herzog TJ
    Gynecol Oncol; 2004 Jan; 92(1):1-3. PubMed ID: 14751129
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.